United States: Litigation Alert: No Exception To Statutory Requirement That A Biosimilar Applicant Provide Notice Of Intent To Market Its Product

Last week in Amgen Inc. v. Apotex Inc., No. 2016-1308 (Fed. Cir. July 5, 2016), a unanimous Federal Circuit panel ruled that under the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), a biosimilar applicant must provide its biologic competitor with at least 180 days' notice of intent to commercially market a biosimilar product.  The decision makes clear that this requirement applies even if the biosimilar applicant participates in the so-called "patent dance."  The panel also restated the Federal Circuit's holding in Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015), that a biosimilar applicant cannot provide the requisite notice until the biosimilar product at issue is approved, or "licensed," by the FDA, but attempted to limit the consequence of that holding by suggesting that the FDA can license a biosimilar product before the expiration of the reference biologic's twelve-year period of exclusivity.  Ultimately, while the Amgen v. Apotex decision favors biologic manufacturers, its long-term import depends on the outcome of Sandoz's pending petition for certiorari before the Supreme Court.

The BPCIA Framework

The BPCIA establishes an abbreviated pathway for regulatory approval of follow-on biologic drugs, known as "biosimilars," and in so doing attempts to balance the interests of those engaging in original biologics discovery with the public's desire for lower cost medical treatment.  Whereas a biologics license application ("BLA") requires extensive clinical data establishing the safety and efficacy of the original biologic product, an abbreviated biologics license application ("aBLA") requires only that the follow-on applicant establish that its product is either "biosimilar" to or "interchangeable" with the previously licensed biologic "reference product."  Compare 42 U.S.C. § 262(a) with id. § 262(k).  In return, the BPCIA establishes a twelve-year period of exclusivity for an original biologic drug, regardless of patent protection, and bars the submission of a biosimilar application for four years, with both periods running from first licensure of the reference product.  Id. § 262(k)(7)(A)–(B).

The BPCIA also establishes a regime to narrow and resolve patent infringement disputes between biologic and biosimilar competitors.  That process, often referred to as the "patent dance," provides for the exchange of information between the biosimilar applicant and reference product sponsor.  Id. § 262(l).  First, within 20 days after an aBLA is accepted by the FDA for review, a biosimilar applicant is to provide to the reference product sponsor a copy of its aBLA as well as information describing its manufacturing process.  Id. § 262(l)(2)(A).  Then, within 60 days of receiving the aBLA, the reference product sponsor is to provide a list of patents that it could reasonably assert against the biosimilar applicant.  Id. § 262(l)(3)(A).  Within 60 days of receiving that list, the biosimilar applicant is to respond with its positions on infringement and validity of those patents as well as with a list of any other patents it believes could be asserted against it.  Id. § 262(l)(3)(B).  Next, the reference product sponsor has 60 days to respond with its own positions on infringement and validity of its patents.  Id. § 262(l)(3)(C).  Following negotiation to limit the patents at issue, the BPCIA then allows the reference product sponsor to bring an action for patent infringement.  Id. § 262(l)(6). Finally, a biosimilar applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of first commercial marketing of the biological product licensed under subsection (k)."  Id. § 262(l)(8)(A).  Such notice allows the reference product sponsor to seek a preliminary injunction prohibiting such activity pursuant to any patent listed by either party as part of the patent dance but excluded from the § 262(l)(6) infringement action.  Id. § 262(l)(8)(B).

In Amgen v. Sandoz, its first decision addressing the BPCIA, the Federal Circuit held that a biosimilar applicant cannot provide its notice of commercial marketing prior to receiving FDA approval for its product.  The Court thus found that Sandoz's § 262(l)(8)(A) notice was ineffective because it was provided before its biosimilar product was licensed. Sandoz's petition for certiorari, which requests review of this finding, is currently pending.  In addition, the Court also held in Amgen v. Sandoz that a biosimilar applicant is not required to engage in the "patent dance," and that Sandoz therefore did not violate the BPCIA in refusing to provide Amgen with its aBLA and manufacturing information.  In the event that Sandoz's petition for review of the notice of commercial marketing issue is granted, Amgen has requested that the Supreme Court also review this latter holding as well.

Factual Background of Amgen v. Apotex

In October 2014, Apotex filed an aBLA with the FDA listing Amgen's Neulasta® as the reference product.  Unlike Sandoz, however, Apotex initiated and fully engaged in the BPCIA's "patent dance."  Apotex timely provided Amgen a copy of its aBLA and manufacturing information in compliance with § 262(l)(2)(A).  After Amgen provided its § 262(l)(3)(A) patent list, Apotex responded with its positions concerning the infringement and validity of those patents.  At the same time that Apotex provided that § 262(l)(3)(B) response, Apotex sent a letter to Amgen providing "notice" of future commercial marketing pursuant to § 262(l)(8)(A), even though it lacked an FDA license for its allegedly "biosimilar" product.  Amgen subsequently provided its § 262(l)(3)(C) response to Apotex.

With the pre-suit portion of the patent dance complete, on August 6, 2015, Amgen sued Apotex for infringement of two of the patents that it had previously identified.  In light of the Federal Circuit's decision in Amgen v. Sandoz, Amgen challenged the effectiveness of Apotex's alleged prior notice of future commercial marketing, seeking a preliminary injunction that would require Apotex to provide § 262(l)(8)(A) notice to Amgen only if and when it receives a license from the FDA and barring any commercial marketing for 180 days from that notice.  In connection with that motion, the parties stipulated that Amgen would be irreparably harmed if Apotex enters the market without giving notice, that the balance of hardships favors Amgen, and that the public interest favors the issuance of an injunction.  The merits of the preliminary injunction therefore turned exclusively on Amgen's likelihood of success on the legal question presented: whether the § 262(l)(8)(A) notice requirement is a mandatory one enforceable by injunction, even if the biosimilar applicant otherwise engaged in the "patent dance."  The district court found that the BPCIA notice requirement is mandatory and issued Amgen's requested injunction.  Apotex appealed.

The Federal Circuit's Decision

The Federal Circuit affirmed the district court's grant of preliminary injunctive relief to Amgen, holding that the § 262(l)(8)(A) post-licensure notice requirement is mandatory and enforceable regardless of whether the biosimilar applicant engages in the patent dance.  After observing that the statutory provision's use of "shall" supports a categorical notice requirement, and that it had already so ruled in Amgen v. Sandoz, the Federal Circuit rejected Apotex's argument that § 262(l)(8)(A) does not apply to biosimilar applicants, such as itself, who comply with the § 262(l)(2) provision seeking to channel any potential patent disputes with the reference product sponsor.  The Court explained that the language of § 262(l)(8)(A) contains no words that make the applicability of its notice rule turn on whether the applicant took the earlier step of initiating the information exchange process by providing its aBLA and manufacturing information to the reference product sponsor in compliance with § 262(l)(2). The Court also elaborated on its understanding of the purpose of the § 262(l)(8)(A) notice requirement as "ensur[ing] that, starting from when the [biosimilar] applicant's product, uses, and processes are fixed by the license, the necessary decision-making regarding further patent litigation is not conducted under time pressure that will impair its fairness and accuracy."  That purpose applies equally to biosimilar applicants who engage in the patent dance, explained the Court, because not all relevant patents are litigated as part of the initial § 262(l)(6) infringement action.

The Federal Circuit also defended its previous holding that § 262(l)(8)(A) notice of intent to commercially market a biosimilar product cannot be provided until the FDA licenses that product.  In particular, the Court addressed the criticism that this ruling effectively extends the twelve-year biologic exclusivity period by 180 days, observing that it "ha[s] been pointed to no reason that the FDA may not issue a license before the 11.5-year mark and deem the license to take effect on the 12-year date."

Finally, the Federal Circuit also held that a preliminary injunction that requires the biosimilar applicant to provide notice under § 262(l)(8)(A) is an appropriate remedy when the applicant fails to do so otherwise, and rejected Apotex's argument that the only available remedy is a patent-merits declaratory judgment action under § 262(l)(9).

Industry Implications

The longevity of the Federal Circuit's decision in Amgen v. Apotex is unclear in light of the pending certiorari petitions challenging the Amgen v. Sandoz decision.  In particular, as mentioned above, Sandoz has specifically challenged the Federal Circuit's finding that a biosimilar applicant cannot provide the required 180-day notice of commercial marketing prior to FDA approval of the biosimilar product, contending that this holding effectively extends the statutory exclusivity period of the reference product beyond what Congress intended.  The decision as to whether to grant certiorari will not occur before the October Term, as the Supreme Court recently called for the views of the Solicitor General.  But ultimately, should certiorari be granted and Sandoz prevail, the pre-licensure notice provided by Apotex would be rendered effective. Thus, if Apotex also files a petition for certiorari in the meantime, it seems likely that the Court would then vacate the Amgen v. Apotex decision and remand it for reconsideration in light of its opinion in the Amgen v. Sandoz case. 

Perhaps with an eye toward the Supreme Court's imminent certiorari ruling, the Federal Circuit responded to criticism of the Amgen v. Sandoz decision by suggesting that post-licensure notice will not extend the twelve-year exclusivity period because the FDA can license a biosimilar product any time after the aBLA is submitted.  In so opining, the Federal Circuit appears to be relying on the BPCIA provision that "[a]pproval of an application" for a biosimilar product "may not be made effective... until the date that is 12 years after the date on which the reference product was first licensed." 42 U.S.C. § 262(k)(7)(A).  It is far from clear, however, whether that provision provides the FDA with the statutory authority to issue such tentative licenses, or whether the FDA must do so even if it does.  Also unclear is whether the courts would interpret § 262(l)(8)(A) to allow a biosimilar applicant to give notice of commercial marketing once it receives a tentative license, or will instead require the license to be effective—and thus the exclusivity period to have ended—before notice can be given.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Oct 2017, Conference, California, United States

CALOBA is excited to bring you our General Counsel (GC) roundtable event. Our distinguished panel of top legal counsel will share their experiences at the helm of some of the top technology companies.

30 Oct 2017, Seminar, California, United States

This program will address some of the hottest legal and policy topics that online platforms have brought to the fore: free speech, hate speech, fake news, privacy and surveillance, artificial intelligence, augmented reality, changing notions of “ownership” of information and software-enabled consumer products, and the perennial issue of copyright.

8 Nov 2017, Conference, California, United States

Fenwick & West is proud to be participating in PLI’s 49th Annual Institute on Securities Regulation scheduled for November 8-10, 2017 at The Roosevelt Hotel in New York City. The Institute is considered the premier conference, as well as one of the longest running, in the securities law field.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.